Services on Demand
Journal
Article
English (pdf)
Article in xml format
Article references
Automatic translation
Send this article by e-mailIndicators
Cited by SciELO 
Access statistics
Related links
Cited by Google 
Similars in
SciELO 
Similars in Google
Share
Permalink
Revista Colombiana de Reumatología
Print version ISSN 0121-8123
Abstract
JAUREGUI, Edwin et al. Colombian Association of Rheumatology. Consensus on recommendations to decrease and discontinue biological therapy in patients with rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis. Rev.Colomb.Reumatol. [online]. 2019, vol.26, n.1, pp.11-23. ISSN 0121-8123. https://doi.org/10.1016/j.rcreue.2018.10.002.
Objective:
The objective of this study was to establish recommendations for the reduction and discontinuation of biological disease-modifying antirheumatic drugs, with the aim of becoming a guide document for health professionals involved in the management of patients with rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis.
Materials and methods:
The recommendations were established through consensus by a panel of experts in rheumatology, and based on the analysis of available scientific evidence obtained from systematic reviews and the clinical experience of the panellists.
Results:
A total of 33 rheumatoid arthritis related studies were included, with 6 psoriatic arthritis related, and 9 ankylosing Spondylitis related. The recommendations for the reduction of biological therapies were made by establishing a plan to determine when and how to reduce the biological disease-modifying antirheumatic drugs in patients with these 3 diseases, and in some cases lead to the discontinuation of these treatments.
Conclusion:
The recommendations established in this document will serve as a guide to improve the efficiency of biological therapy in these diseases, reduce the variability in clinical practice, and establish an adequate risk/benefit ratio.
Keywords : Rheumatoid arthritis; Psoriatic arthritis; Ankylosing spondylitis; Biological drugs; Dose reduction; Biologic disease-modifying; antirheumatic drug; Conventional disease-modifying; antirheumatic drug..
